Effects of Timolol and Latanoprost on Respiratory and Cardiovascular Status in Elderly Patients With Glaucoma

Ergin, Ahmet; Örnek, Kemal; Güllü, Reyhan; Bulcun, Emel; Ekici, Mehmet; Ekici, Aydanur

doi:10.1089/jop.2008.0137

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 47 , 49 , 57 And lastly, although systemic side effects of topical medications are uncommon, they can be very serious. 58 , 59 …”

Section: Limitations Of Topical Medical Therapymentioning

confidence: 99%

“…47,49,57 And lastly, although systemic side effects of topical medications are uncommon, they can be very serious. 58,59 In addition to side effects and nonadherence, topical medical therapy is limited by the inherent difficulty of penetrating the corneal surface, the eye's natural barrier, to deliver medication in a consistent 24/7 manner. This difficulty may contribute to the fact that although all glaucoma medications have proven IOP-lowering efficacy, they are still not a sure-fire way to eliminate the risk of glaucoma progression.…”

Section: Years Of Topical-medication-first Glaucoma Therapymentioning

confidence: 99%

See 1 more Smart Citation

Alternatives to Topical Glaucoma Medication for Glaucoma Management

Bedrood,

Berdahl,

Sheybani

et al. 2023

OPTH

View full text Add to dashboard Cite

Topical glaucoma medications have favorable safety and efficacy, but their use is limited by factors such as side effects, nonadherence, costs, ocular surface disease, intraocular pressure fluctuations, diminished quality of life, and the inherent difficulty of penetrating the corneal surface. Although traditionally these limitations have been accepted as an inevitable part of glaucoma treatment, a rapidly-evolving arena of minimally invasive surgical and laser interventions has initiated the beginnings of a reevaluation of the glaucoma treatment paradigm. This reevaluation encompasses an overall shift away from the reactive, topical-medication-first default and a shift toward earlier intervention with laser or surgical therapies such as selective laser trabeculoplasty, sustained-release drug delivery, and micro-invasive glaucoma surgery. Aside from favorable safety, these interventions may have clinically important attributes such as consistent IOP control, cost-effectiveness, independence from patient adherence, prevention of disease progression, and improved quality of life.

show abstract

“… 47 , 49 , 57 And lastly, although systemic side effects of topical medications are uncommon, they can be very serious. 58 , 59 …”

Section: Limitations Of Topical Medical Therapymentioning

confidence: 99%

Section: Years Of Topical-medication-first Glaucoma Therapymentioning

confidence: 99%

Alternatives to Topical Glaucoma Medication for Glaucoma Management

Bedrood,

Berdahl,

Sheybani

et al. 2023

OPTH

View full text Add to dashboard Cite

show abstract

“…Issues such as subclinical reversible airways disease, headache, dizziness and drowsiness may arise when utilising drugs like timolol or brimonidine. 214,215 In the potentially vulnerable geriatric population, these may lead to more severe consequences such as falls. In some cases, conducting preliminary cardiac (such as sphygmomanometry or electrocardiogram) and respiratory (such as spirometry) have been suggested to screen for subclinical disease.…”

Section: Patient Agementioning

confidence: 99%

Management of open‐angle glaucoma by primary eye‐care practitioners: toward a personalised medicine approach

Phu

Agar

Wang

et al. 2021

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Glaucoma is the leading cause of irreversible blindness worldwide. As a chronic disease, glaucoma presents a significant burden to the individual, health-care provider and the health-care system. Currently, strategies for treating glaucoma are focused on lowering intraocular pressure, which is aimed at slowing or arresting disease progression over time. This is the only current accepted therapeutic strategy for glaucoma, and can be achieved using topical drugs, laser trabeculoplasty, filtration surgery or cyclodestructive techniques. The lowering of intraocular pressure has been wellsupported by numerous large-scale seminal clinical trials in primary open-angle glaucoma, in both its early and advanced stages. Although such guidance remains current, in the last 10-years, there has been a significant evolution in preferred first-line therapies in the treatment of open-angle glaucoma with a resultant shift in practice patterns, particularly early in the course of the disease. These changes reflect both from the perspective of the doctor -in titrating the most effective and least risky treatment modality -and the perspective of the patient, in consenting to a treatment that preserves vision and results in minimal negative impact on quality of life. In this review, the most recent evidence regarding treatment modalities for early primary open-angle glaucoma is presented and an updated framework for management guidance is proposed.

show abstract

“… 6 - 10 Noncompliance is especially significant when patients use more than one medication 11 and ultimately leads to suboptimal, inconsistent IOP control. By replacing or decreasing the need for topical medications, LTP can improve IOP control, reduce systemic side effects such as cardiovascular and respiratory adverse events and depression 12 13 and local side-effects, such as eyelid dermatitis, lacrimal system scarring, ocular discomfort upon instillation, tear film instability, subconjunctival fibrosis, conjunctival inflammation and epithelium changes and corneal surface and endothelial impairment. 14 …”

Section: Introductionmentioning

confidence: 99%

Selective Laser Trabeculoplasty: A Clinical Review

Skaat¹

2013

Journal of Current Glaucoma Practice

View full text Add to dashboard Cite

Selective laser trabeculoplasty (SLT) is a safe and effective treatment modality for lowering the intraocular pressure in patients with glaucoma. It achieves its results by selective absorption of energy in the trabecular pigmented cells, sparing adjacent cells and tissues from thermal damage, with minimal morphological tissue alteration following treatment. On the basis of the peer-reviewed medical literature, SLT is efficacious in lowering IOP, as initial treatment or when medical therapy is insufficient in all types of open-angle glaucoma in all races. SLT achieves intraocular pressure reduction similar to that of argon laser trabeculoplasty but without the tissue destruction and side effects. Observed side effects following SLT were almost uniformly transient and minor. We review highlights of recently published studies on the mechanisms and clinical outcome of SLT in order to address frequently raised issues pertinent to SLT in the clinical practice.Key messages: Selective laser trabeculoplasty is a safe and effective treatment modality for lowering the intraocular pressure in patients with glaucoma.How to cite this article: Alon S. Selective Laser Trabeculoplasty: A Clinical Review. J Current Glau Prac 2013; 7(2):58-65.

show abstract

Effects of Timolol and Latanoprost on Respiratory and Cardiovascular Status in Elderly Patients With Glaucoma

Cited by 6 publications

References 21 publications

Alternatives to Topical Glaucoma Medication for Glaucoma Management

Alternatives to Topical Glaucoma Medication for Glaucoma Management

Management of open‐angle glaucoma by primary eye‐care practitioners: toward a personalised medicine approach

Selective Laser Trabeculoplasty: A Clinical Review

Contact Info

Product

Resources

About